Skip to main content
TipRanks
Go Ultimate75% OFF

Chunghwa Chemical Synthesis & Biotech Co., Ltd. Class A (1762) AI Stock Analysis

TW:1762

Chunghwa Chemical Synthesis & Biotech Co., Ltd. Class A

(TWSE:1762)

Select Model
Rating:38Underperform
Price Target:TWD 29.00â–¼(-3.81% Downside)
Action:initiatedcoverage
Date:11/10/26

The overall score is very low, driven primarily by a collapse in financial performance, with the company's revenue in freefall and profitability turning deeply negative. This fundamental distress is strongly confirmed by extremely bearish technicals, with the stock in a clear downtrend and showing no signs of momentum. The negative earnings and negligible dividend yield offer no valuation support. The company's trajectory is unsustainable without a major turnaround.

Positive Factors
Moderate LeverageDebt remains moderate at about 0.26 times equity, limiting refinancing pressure and preserving financial flexibility. This gives the company more capacity to manage the downturn and fund operations than a highly leveraged balance sheet would allow.
Negative Factors
Revenue ContractionRevenue fell about 18% year over year in 2025, indicating weaker demand, pricing, or product mix at the latest reporting point. A sustained top-line contraction would reduce operating leverage, limit reinvestment, and make recovery dependent on restoring sales momentum.

Chunghwa Chemical Synthesis & Biotech Co., Ltd. Class A (1762) vs. SPDR S&P 500 ETF (SPY)

-20%0%20%40%60%80%TW:1762+23.06%SPY+11.99%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
TWD 2.22B
Dividend Yield
0.64%
Average Volume (3M)
95.33K
Price to Earnings (P/E)
-55.8
Beta (1Y)
0.67
Revenue Growth
2.05%
EPS Growth
―
Country
TW
Employees
243
Sector
Healthcare
Sector Strength
51
Industry
Medical - Pharmaceuticals

Chunghwa Chemical Synthesis & Biotech Co., Ltd. Class A Business Overview & Revenue Model

Company Description

Based in New Taipei City, Taiwan, Chunghwa Chemical Synthesis & Biotech Co., Ltd., established in 1964 and previously known as China Chemical Synthesis Industry Co., Ltd., specializes in the development, production, and distribution of active pharmac...

Chunghwa Chemical Synthesis & Biotech Co., Ltd. Class A Financial Statement Overview

Summary

Financial performance is critically weak. The income statement shows a severe revenue decline and negative gross margins, indicating the core business is loss-making. The cash flow score is very low due to volatile and declining cash generation. The balance sheet is the only relative bright spot with low leverage, but the trend of increasing debt and shrinking equity is concerning. The overall financial health is poor.

Income Statement

8Very Negative

Balance Sheet

55Neutral

Cash Flow

30Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Mar 2023Dec 2021
Income Statement
Total Revenue934.29M804.88M1.35B2.09B2.12B1.93B
Gross Profit167.67M-8.86M394.32M757.31M961.76M949.39M
EBITDA151.05M-47.60M277.66M545.93M743.72M651.27M
Net Income-51.70M-243.85M53.03M264.91M465.87M400.78M
Balance Sheet
Total Assets4.36B4.32B4.76B5.17B4.56B4.38B
Cash, Cash Equivalents and Short-Term Investments329.96M216.44M222.28M269.57M300.61M195.25M
Total Debt755.63M805.86M858.17M1.21B604.54M753.55M
Total Liabilities1.16B1.23B1.41B1.82B1.37B1.49B
Stockholders Equity3.20B3.09B3.36B3.35B3.19B2.89B
Cash Flow
Free Cash Flow248.54M80.28M362.96M-517.83M357.60M-186.27M
Operating Cash Flow290.90M142.61M467.65M-66.27M733.78M219.18M
Investing Cash Flow-60.36M-61.80M-100.10M-461.32M-376.18M-802.75M
Financing Cash Flow-116.12M-86.03M-415.72M496.57M-253.32M630.62M

Chunghwa Chemical Synthesis & Biotech Co., Ltd. Class A Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

TW:1762 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
TW:8432TW:843286OutperformTWD 2.36B11.08―4.28%20.56%67.85%
TW:1780TW:178071OutperformTWD 2.45B20.60―5.57%――
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
TW:8403TW:840349NeutralTWD 2.46B12.09―3.35%6.25%14.37%
TW:4108TW:410847NeutralTWD 2.03B-75.06――1.10%56.29%
TW:1762TW:176238UnderperformTWD 2.32B-55.83―0.64%2.05%―

* Healthcare Sector Average

Performance Comparison

-25%0%25%50%75%TW:1762TW:1780TW:4108TW:7860TW:8403TW:8432Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
TW:1762 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
TW:1762Chunghwa Chemical Synthesis & Biotech Co., Ltd. Class A30.155.8023.82%
TW:1780Allied Biotech Corp22.453.4518.15%
TW:4108Phytohealth Corporation10.20-3.70-26.62%
TW:7860Teh Seng Pharmaceutical Mfg Co Ltd77.509.9814.78%
TW:8403ShareHope Medicine Co., Ltd.17.90-4.93-21.58%
TW:8432TSH Biopharm Corp. Ltd.61.0011.0822.20%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026